FVD - First Trust Value Line Dividend Index Fund

NYSEArca - Nasdaq Real Time Price. Currency in USD
34.92
+0.01 (+0.03%)
As of 9:50AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close34.91
Open34.84
Bid34.86 x 3100
Ask34.87 x 800
Day's Range34.80 - 34.93
52 Week Range27.59 - 35.16
Volume112,253
Avg. Volume987,030
Net Assets7.18B
NAV34.92
PE Ratio (TTM)N/A
Yield2.09%
YTD Return21.25%
Beta (3Y Monthly)0.73
Expense Ratio (net)0.70%
Inception Date2003-08-19
Trade prices are not sourced from all markets
  • A Bunch of Dividend ETFs Hitting All-Time Highs
    Zacks

    A Bunch of Dividend ETFs Hitting All-Time Highs

    Dividend-focused ETFs are in demand given investors' drive for higher income.

  • Dividend ETF (FVD) Hits New 52-Week High
    Zacks

    Dividend ETF (FVD) Hits New 52-Week High

    This dividend ETF has hit a new 52-week high. Are more gains in store?

  • Business Wire

    First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds

    First Trust Advisors L.P. announces the declaration of distributions for 115 exchange-traded funds advised by FTA.

  • A Dividend ETF Investing Guide
    Zacks

    A Dividend ETF Investing Guide

    Dividend paying securities are the major source of consistent income for investors to create wealth when returns from the equity market are at risk.

  • Stanley Black & Decker: Institutional Holdings
    Market Realist

    Stanley Black & Decker: Institutional Holdings

    The 13F filings on September 30 indicated that institutional investors own ~87.9% of Stanley Black & Decker’s (SWK) outstanding shares. A total of 817 institutions hold Stanley Black & Decker. Among the institutions, 323 increased their positions on Stanley Black & Decker, 354 reduced their positions, and 140 maintained their positions.

  • Sanofi: Analysts’ Recommendations on October 30
    Market Realist

    Sanofi: Analysts’ Recommendations on October 30

    Wall Street analysts expect Sanofi’s (SNY) third-quarter revenues to increase 3.3% to 9.3 billion euros. Sanofi’s stock price has decreased nearly 11.0% over the last 12 months. The stock price has decreased ~1.7% in 2018 year-to-date.

  • GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates
    Market Realist

    GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates

    GlaxoSmithKline (GSK) is a leading British multinational pharmaceutical company. It reports its financial results in British pounds and is expected to release its third quarter of 2018 earnings on October 31. The growth drivers for GlaxoSmithKline include new respiratory products and HIV products in the Pharmaceuticals segment.

  • How Novartis’s Sandoz Performed in the Third Quarter
    Market Realist

    How Novartis’s Sandoz Performed in the Third Quarter

    Novartis’s (NVS) Sandoz is a market leader in differentiated generics. Sandoz reported a 6% decrease in its YoY revenues to ~$2.42 billion during the third quarter of 2018 as compared to $2.58 billion during the third quarter of 2017. The decrease includes a 4% decrease in operating revenues and a 2% negative impact of foreign exchange during the quarter.

  • A Guide to Dividend ETF Investing
    Zacks

    A Guide to Dividend ETF Investing

    We have highlighted 10 most popular dividend ETFs for investors seeking yields and returns in a rocky market.

  • Novartis Missed Revenue Estimates in Q3 2018
    Market Realist

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.

  • Novartis in Q3 2018: Analysts Expect Revenue Growth
    Market Realist

    Novartis in Q3 2018: Analysts Expect Revenue Growth

    Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.

  • A Look at the Performance of Novartis’s Alcon
    Market Realist

    A Look at the Performance of Novartis’s Alcon

    Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise including the 5% increase in its operating revenue and the 2% favorable impact of foreign exchange. Alcon announced in September 2018 that it would be locating its future headquarters in Geneva, Switzerland, following the completion of the proposed spinoff from Novartis.

  • How Novartis’s Sandoz Business Has Been Performing Recently
    Market Realist

    How Novartis’s Sandoz Business Has Been Performing Recently

    Sandoz reported nearly flat revenue of ~$2.46 billion in the second quarter driven by a 2% favorable impact of foreign exchange and offset by a 2% fall in operating revenue in the quarter. The segment’s biopharmaceuticals portfolio reported revenue of $363 million in the second quarter, a 34% rise in operating revenue driven by an increase in US and European sales following the increased demand of the drugs Omnitrope and Zarxio in US markets and Erelzi and Rixathon in European markets.

  • How GlaxoSmithKline’s Pharmaceutical Business Performed
    Market Realist

    How GlaxoSmithKline’s Pharmaceutical Business Performed

    GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products. During the second quarter of 2018, the Pharmaceutical segment reported a 1% increase in operating revenues to ~4.23 billion pounds.